27 Oct 2015

Ganfort (Bimatoprost / Timolol) - Italia

ATC: S01ED
SENSORY ORGANS
OPHTHALMOLOGICALS
ANTIGLAUCOMA PREPARATIONS AND MIOTICS
BETA BLOCKING AGENTS
Ganfort

Last Updated on 27 Oct 2015 by EPG Health Media Staff

Suggest content to an epgonline.org editor - or let us know about a mistake you have spotted on this page

Ganfort Indication

Riduzione della pressione intraoculare (PIO) in pazienti adulti con glaucoma ad angolo aperto o con ipertensione oculare, che non rispondono adeguatamente ai beta-bloccanti o agli analoghi delle prostaglandine per uso topico.

 

Ganfort Generic Name

Bimatoprost / Timolol

Type

POM

Summary Product Characteristics (SPCs) Links
Riassunto delle Caratteristiche del Prodotto - Ganfort (external site)

Related Learning Zones

Hypogonadism Knowledge Centre

Hypogonadism Knowledge Centre

The Hypogonadism Knowledge Centre provides healthcare professionals with free access to disease awareness sections such as epidemiology, pathophysiology, signs and symptoms, treatment options to assist the process of diagnosis, treatment and monitoring of patients with the condition. The regularly updated publications digest area contains analysis and comment on recent scientific articles related to male hypogonadism.

G.MKT.GM.MH.01.2016.0364

Obesity CME series

Obesity CME series

This European Obesity Initiative CME series contains three online modules, which are ideal for healthcare professionals looking to widen their understanding of obesity as a serious medical illness. Each module is EACCME-accredited and free to complete. Successful completion of the series will earn participants a combined total of 5 European CME credits (ECMECs).

Selected content related to Ganfort (Bimatoprost / Timolol)

Guidelines

Ganfort Marketing Information

Ganfort Generic Name
Bimatoprost / Timolol
Marketing Company
Allergan Pharmaceuticals Ireland
Drug Type
POM
Date of Issue, Marketing Authority

19/05/2006

Related Drugs - Eye Health and Disorders

Back to top